Latest News and Decisions

Latest News and Decisions

At the meeting of 2 August 2017 the RMA:

Determined Statements of Principles (SOPs) for:

Condition SOPs
influenza 44/2017 45/2017
malaria 46/2017 47/2017
alcohol use disorder 48/2017 49/2017
rheumatoid arthritis 50/2017 51/2017

These SOPs revoke the SOPs previously determined for these conditions.

Determined New Statements of Principles (SOPs) for:

Condition SOPs
tooth wear 52/2017 53/2017
popliteal entrapment syndrome 54/2017 55/2017
benign paroxysmal positional vertigo 56/2017 57/2017

Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017

Condition SOPs
acoustic neuroma 58/2017 58/2017
acquired cataract 58/2017 58/2017
acute lymphoblastic leukaemia 58/2017 58/2017
acute myeloid leukaemia 58/2017 58/2017
adenocarcinoma of the kidney 58/2017 58/2017
Alzheimer-type dementia 58/2017  
angle-closure glaucoma 58/2017 58/2017
aortic stenosis 58/2017 58/2017
atherosclerotic peripheral vascular disease 58/2017 58/2017
benign neoplasm of the eye and adnexa 58/2017 58/2017
cardiomyopathy 58/2017 58/2017
carotid arterial disease 58/2017 58/2017
cerebral meningioma 58/2017 58/2017
cerebrovascular accident 58/2017 58/2017
chronic gastritis and chronic gastropathy 58/2017 58/2017
chronic myeloid leukaemia 58/2017 58/2017
chronic pancreatitis 58/2017 58/2017
cirrhosis of the liver 58/2017  
erectile dysfunction 58/2017 58/2017
external burn 58/2017 58/2017
fibrosing interstitial lung disease 58/2017 58/2017
gastric ulcer and duodenal ulcer 58/2017 58/2017
goitre 58/2017 58/2017
Graves' disease 58/2017 58/2017
Hashimoto's thyroiditis 58/2017 58/2017
heart block 58/2017 58/2017
hypothyroidism 58/2017 58/2017
ischaemic heart disease 58/2017 58/2017
malignant neoplasm of the bile duct 58/2017 58/2017
malignant neoplasm of the bladder 58/2017 58/2017
malignant neoplasm of bone and articular cartilage 58/2017 58/2017
malignant neoplasm of the brain 58/2017 58/2017
malignant neoplasm of the breast 58/2017 58/2017
malignant neoplasm of the cerebral meninges 58/2017 58/2017
malignant neoplasm of the colorectum 58/2017 58/2017
malignant neoplasm of the endometrium 58/2017 58/2017
malignant neoplasm of the gallbladder 58/2017 58/2017
malignant neoplasm of the liver 58/2017 58/2017
malignant neoplasm of the lung 58/2017 58/2017
malignant neoplasm of the oesophagus 58/2017 58/2017
malignant neoplasm of the ovary 58/2017 58/2017
malignant neoplasm of the renal pelvis and ureter 58/2017 58/2017
malignant neoplasm of the salivary gland 58/2017 58/2017
malignant neoplasm of the stomach 58/2017 58/2017
malignant neoplasm of the thyroid gland 58/2017 58/2017
malignant neoplasm of unknown primary site 58/2017 58/2017
mesothelioma 58/2017 58/2017
multiple sclerosis 58/2017  
myelodysplastic syndrome 58/2017 58/2017
myeloma 58/2017  
narcolepsy 58/2017 58/2017
neoplasm of the pituitary gland 58/2017  
non-aneurysmal aortic atherosclerotic disease 58/2017 58/2017
non-Hodgkin's lymphoma 58/2017  
non-melanotic malignant neoplasm of the skin 58/2017 58/2017
open-angle glaucoma 58/2017 58/2017
optochiasmatic arachnoiditis 58/2017 58/2017
osteomyelitis 58/2017 58/2017
otitis externa 58/2017 58/2017
otitis media 58/2017 58/2017
peritoneal adhesions 58/2017 58/2017
renal artery atherosclerotic disease 58/2017 58/2017
soft tissue sarcoma 58/2017 58/2017
tinnitus 58/2017 58/2017
trigeminal neuropathy 58/2017 58/2017

The above SOPs take effect from 18 September 2017.

Summary of Changes

Finalised Declaration for:

Condition Declaration Reasons for Decision
chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquine PDF Word PDF Word

Completed Investigations

The above determinations and declarations conclude the previously advertised investigations into:

New Investigation

Decided to advertise the following investigation:

The above declaration and investigation notice appear in the Government Notices Gazette of 29 August 2017.